Form 4: Harmony Biosciences CFO Sells Shares Under 10b5-1 Plan

Harmony Biosciences' Chief Financial Officer, Sandip Kapadia, sold 3,746 shares of common stock for a weighted average price of $37.152 per share as part of a pre-arranged trading plan.

Summary

• Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), reported the sale of common stock.
• A total of 3,746 shares of common stock were disposed of on January 26, 2026.
• The shares were sold at a weighted average price of $37.152 per share, with individual transaction prices ranging from $36.57 to $37.70.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan, indicating it was pre-scheduled.
• Following this transaction, Sandip Kapadia beneficially owns 24,521 shares of Harmony Biosciences common stock.
• The filing also corrected a misstatement from a previous Form 4 filed on January 26, 2026, regarding the number of beneficially owned shares.

Sentiment

Score: 5

Explanation: The filing reports a planned insider sale under a Rule 10b5-1 trading plan, which is a neutral event as it's pre-scheduled. It also includes a correction of a previous filing, which is a compliance-related update, leading to a neutral overall sentiment.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, which indicates a pre-arranged, non-discretionary transaction, mitigating concerns about opportunistic insider selling.

Negatives

• Insider selling, even if planned, can sometimes be perceived negatively by the market as it reduces management's direct equity stake in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan.
• The price reported is a weighted average price, and full information regarding shares sold at each separate price within the range will be provided upon request.
• A previous Form 4 filed on January 26, 2026, inadvertently misstated the number of shares beneficially owned, and that number has been corrected in this filing.

Industry Context

This Form 4 filing is specific to an insider transaction at Harmony Biosciences and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: May observe the reduction in insider ownership, though the 10b5-1 plan context generally lessens immediate concern. The correction ensures accurate public record of insider holdings.

Key Dates

Recommendation

This filing details a routine, pre-scheduled insider stock sale by the CFO under a Rule 10b5-1 trading plan and corrects a previous reporting error. It does not provide new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is a compliance-related event rather than an indicator of a shift in company prospects.

Keywords

Harmony Biosciences, HRMY, Sandip Kapadia, CFO, Insider Trading, Stock Sale, Form 4, 10b5-1 Plan